---
title: "Descartes-08 in Generalized myasthenia gravis: Conclusions"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Conclusions. 1 evidence topic quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary/conclusions"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Conclusions

<a id="heading-1.1.4"></a>

## 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

### Summary

Descartes-08 holds FDA Orphan Drug Designation for myasthenia gravis (dated 11/08/2022) and Regenerative Medicine Advanced Therapy designation (May 2024), and the FDA agreed to the design of the phase 3 AURORA trial under a Special Protocol Assessment in January 2025; the registry lists actual AURORA enrollment of 128 participants (the company planned approximately 100), the company expects topline data in the first quarter of 2027 and a biologics license application in mid-2027, and it has no products approved for sale. In the phase 2b portion of MG-001, an MGC improvement of 5 points or more at month 3 occurred in 10 of 15 participants (66.7%) receiving Descartes-08 and 3 of 11 (27.3%) receiving placebo (P = 0.0472) in a primary efficacy population of 26 of the 36 randomized participants, and the mean MG-ADL reduction in the Descartes-08 group was −4.8 at month 12, after all 11 placebo participants had received open-label Descartes-08 following month 3. During the study, adverse events occurred in 17 of 20 (85.0%) and 13 of 16 (81.3%) participants and infusion-related reactions in 16 (80.0%) and 9 (56.3%), the only treatment-related serious adverse event was a grade 3 infusion-related reaction, and no anaphylaxis was reported across 14 participants and 88 infusions in the earlier phase 1b/2a portion. The phase 2b results are limited by the sample size, a change of the primary endpoint from the MG-ADL score to the MGC score after 44 participants had enrolled and before unblinding, imbalance in disease duration and thymoma between groups, secondary comparisons that did not meet the threshold for formal testing, and infusion-related reactions that may have affected assessment of severity scales. A 2026 guidance statement advises clinicians to initiate targeted therapies when conventional therapy does not achieve symptom control within 6 to 12 months, the company states that complement and FcRn agents are typically administered continually and that Descartes-08 is designed for outpatient administration without preconditioning chemotherapy, and a 2026 article states that, at present, CAR-T therapy “should be considered experimental and delivered in specialised centres, pending longer term safety and durability data”. The report holds no price, budget impact model, or cost-effectiveness analysis for Descartes-08; comparator evidence includes a 2022 analysis in which the incremental cost-effectiveness ratio was never less than $3.8 million per QALY/evLYG for eculizumab and $1.7 million per QALY/evLYG for efgartigimod, and CAR-T cost evidence includes B-cell lymphoma and systemic lupus erythematosus settings.

Source: [FDA Orphan Drug Designations and Approvals (2022)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=909722); [Cartesian Therapeutics RMAT designation press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-receives-fda-regenerative-medicine); [Cartesian Therapeutics Special Protocol Assessment press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-fda-special-protocol-assessment); [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247); [Cartesian Therapeutics full year 2025 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-full-year-2025-financial-results); [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial); [Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000111/rnac-20260930.htm); [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/); [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/); [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/); [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm); [Cartesian Therapeutics K2 HealthVentures financing press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-secures-150-million-non-dilutive); [Bradhurst et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13630046/); [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/); [Di et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11340641/); [Kumar and Kim (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13155473/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
